• Nextech AR signed a definitive agreement to acquire UK-based spatial computing company ARWAY Ltd. in a deal that allows it to become a metaverse company
• Nextech announced it had begun integrating HoloX into Microsoft’s HoloLens2, with the integration expected to enable users to navigate the application through eye-tracking and hand gestures
• The company also announced Ryerson University had ordered an additional 35 AR labs for its biology, chemistry, and biochemistry departments
• Nextech is intent on creating shareholder value by integrating the amazing technologies it has created into a single platform that revolves around the metaverse

Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), a company bridging physical and digital worlds through its augmented reality (“AR”) platforms, believes that utilizing live streaming human holograms will result in an explosion of new use cases, as the holograms are destined to play a significant role in global entertainment, commerce, and learning (https://ibn.fm/EQwGH). Given the recent developments at Nextech, this belief is surely becoming a reality. Nextech announced August 10 it had signed a definitive agreement under which it will acquire UK-based spatial computing company ARWAY Ltd. (“ARway”) for approximately $1 million in an all-stock transaction, as well as hire the key founders Baran Korkmaz and Nikhil Sawlani. The acquisition provides Nextech with the technology, in the form of a spatial mapping platform, that allows it to become a metaverse company (https://ibn.fm/ZfcFy). ARway is a Unity-based spatial mapping platform that uses AI to scan and recognize surroundings for hyper-accurate location-based 3D mapping, providing users with an Augmented Reality Software Kit (“SDK”) to frame the digital world in a few minutes. This 3D mapping technology and its AR cloud, combined with Nextech’s scalable solutions for HoloX Human Holograms, AR advertising, AR portals, and AR e-commerce, position NTAR as a leader in the race to the metaverse. In describing the concept of the metaverse during an interview published on the company’s YouTube channel (https://ibn.fm/tIHfM), Nextech CEO Evan Gappelberg likened it to a more experiential AR cloud, further noting that it constitutes persistent augmented reality (“AR”) experiences. “When you think about the top of the mountain in the world of AR, the metaverse is the top of the mountain. There’s really nothing above the metaverse; it is the highest activity or business opportunity that we can actually pursue,” he stated. Facebook (NASDAQ: FB), Epic Games, Microsoft (NASDAQ: MSFT), and others have all identified the metaverse as the future of the internet and computing itself. However, according to Gappelberg, the metaverse is nothing exciting without the content. This is why the company sees it as an opportunity, leading to the focus on creating mini-metaverses – Nextech aims to populate the metaverse with content such as products and holograms (through HoloX). “We think that the mini-metaverse business use case is here to stay, and the implications for future growth are significant. Nextech’s mini-metaverse offering will be available to brands and companies that want to create mini-multiverses based on a geolocation like museums, corporate headquarters, theme parks, sports stadium, university campuses, and more,” explained Gappelberg. Further, as an integral part of Nextech’s mini-metaverse vision, the HoloX, its mixed reality (“MR”) human hologram solution expected to launch in Q3 2021, recently received a major boost when the company announced August 5 that it had begun integrating HoloX into Microsoft’s HoloLens2. Through this implementation, users will be able to navigate the application through eye-tracking and hand gestures thanks to supported gesture controls across HoloX’s UI and UX (https://ibn.fm/nkl71). “We are starting with Microsoft as they are clearly targeting HoloLens at corporations and the government, places where we already have customer relationships, and we see very specific use cases for our holograms,” said Gappelberg. The HoloLens initiative is being designed to provide a more realistic feeling of human hologram presence, beyond what other in-market solutions are capable of currently. Nextech sees the project as an important building block that sets it up for future success. Nextech also announced it had received from Ryerson University, a globally recognized leader in higher education with over 46,000 students, an order for an additional 35 AR labs for its biology, chemistry, and biochemistry departments. Once these labs are complete, the institution will have one of the largest known AR immersive learning programs globally (https://ibn.fm/4NT8V). “These new labs are in addition to the fifty labs developed for the 2020/2021 school year and the further AR labs produced through the RALE AR Lab Builder Program, a Government of Ontario Initiative in Partnership with Ryerson University and Nextech AR and will be available province-wide to institutions of higher education in 2022,” reads the press release. Nextech is availing AR to education institutions through EdTechX, a Microsoft Azure-based platform that enables education institutions to add valuable, immersive digital experiences to learning. With EdTechX and HoloX being just some of several amazing technologies Nextech has created so far, the company, which aims to become a leader in the AR space, believes that integrating such technologies in one unified metaverse-centric platform will create tremendous value for its shareholders. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• Recently uplisted to Nasdaq, trading under symbol “KAVL”
• KAVL plans to launch proprietary line of CBD products under its Kaival Labs subsidiary, marking the first Kaival-branded product
• Company sent LOI to potential launch partner for in-house and white-label production

Following its recent uplist to the Nasdaq exchange, Kaival Brands Innovations Group (NASDAQ: KAVL), a company focused on growing and incubating innovative and profitable products into mature and dominant brands, recently announced plans to launch a new line of cannabidiol (“CBD”) products (https://ibn.fm/7Lcd4). The company intends to follow a similar design path set by its highly successful Bidi(R) Stick product, using the same first-in-class, patented delivery mechanism that gives its loyal consumer base a unique and premium vaping experience. Along with providing users with a convenient, smoke-free delivery method for CBD, KAVL’s industrial-grade hemp formula promises greater bio-availability than many market competitors, resulting in less product used and an overall superior consumer experience. “I am excited to announce the upcoming launch of our new, lab-developed, proprietary CBD products,” said Kaival Brands Founder and CEO Niraj “Raj” Patel. “Our mission is to set new industry standards by providing the highest quality and most effective products in the hemp CBD marketplace.  Our focus is to help people improve their lives by providing a product that maximizes the potential health benefits hemp CBD has to offer.” As part of KAVL’s go-to-market strategy, the company recently announced that it sent an LOI to a potential launch partner to produce its hemp-based products in addition to white-label, wholesale solutions for other product manufacturers. “We are excited for both new and existing adult consumers 21 and older to experience the same class-leading quality that they have become accustomed to with our BIDI(R) Stick offering, which is the number one ENDS product in the U.S. market,” said Patel. “Our agenda has not changed. Our goal is to continue to develop and market alternatives for current adult users of combustible tobacco looking to transition away from legacy tobacco products. Our new Hemp product line represents another avenue in fulfilling our mission.” All CBD products proposed by KAVL will be produced and distributed in compliance with the 2018 Farm Bill that defines hemp as the plant Cannabis sativa and any part of the plant with a delta-9 THC concentration of not more than 0.3 percent by dry weight. In addition, KAVL is committed to responsible marketing, strictly supports age-verification standards, and maintains compliance with all federal, state, and local guidelines and regulations. Headquartered in Grant, Florida, Kaival Brands Innovations Group Inc. operates under a mission to set the highest standard and elevate the adult consumer experience for vaping. The company was recently uplisted to Nasdaq and is now trading under the symbol “KAVL”. For more information, visit the company’s website at www.KaivalBrands.com. NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

• Mobius Interactive  will be promoting Serie A football matches in Brazil, running on Band, ESPN and Fox, with the Mobius.bet brand.
• Each match will feature at least one of the Big 6 Teams in Italian football: Udinese vs. Juventus; Sampdoria vs. AC Milan; Hellas Verona vs. Inter Milan; Genoa vs. Napoli; and U.S. Salernitana 1919 vs. AS Roma
• Brazil is the largest gaming market in Latin America. The industry is experiencing unprecedented growth; Mobius Interactive  is uniquely positioned to take full advantage of this major expansion

Mobius Interactive Ltd., an international online gaming operator, has announced that its flagship brand Mobius.bet will be sponsoring Italy Serie A football games in Brazil in August, running on Band, ESPN and Fox. Serie A TIM is a professional league competition for football clubs at the top of the Italian football league. Lega Serie A was created for the 2010-2011 season and is regarded as one of the best football leagues in the world. In August, Mobius.bet will be advertising during the following Serie A games—each match featuring one of Italy’s Big 6 Teams:

• 08/22/2021: Udinese vs. Juventus
• 08/23/2021: Sampdoria vs. AC Milan
• 08/27/2021: Hellas Verona vs. Inter Milan
• 08/29/2021: Genoa vs. Napoli
• 08/29/2021: U.S. Salernitana 1919 vs. AS Roma

In the first game, Cristiano Ronaldo, and Leonardo Bonucci (Euros winner) will take to the field for Juventus, alongside Brazil’s own Arthur Melo, Danilo, and Alex Sandro. The second game features AC Milan’s Zlatan Ibrahimovic in a match with Sampdoria. The third game sponsored by Mobius.bet will include Inter Milan legends Romelu Lukaku and Alexis Sanchez. At the end of the month, veteran Napoli player Lorenzo Insigne will go up against Genoa. Roma’s newly appointed Jose Mourinho joins Brazil’s Roger Ibanez and Daniel Fuzato on the field against U.S. Salernitana 1919. Brazil is the largest Esports and gaming market in Latin America. While this industry is experiencing unprecedented growth, Mobius.bet is perfectly-positioned to take advantage of this lucrative emerging market. Mobius Interactive CEO and Co-Founder Lynn Pearce describes this unique opportunity: “As we go to market in Brazil, Mobius.bet will be showcased, featuring many of the best football players in the world. With our top sponsorship of the World Cup Qualifiers, coupled with our matches with Serie A, we couldn’t have asked for a better situation for our Brazilian launch.” The Brazilian launch of Mobius.bet includes a top sponsorship on Globo.tv of the 2021 FIFA WORLD CUP Qualifiers: (https://ibn.fm/XQBbV) Mobius Interactive is seeing great success since its launch during lockdown in 2020, culminating recently in a coveted nomination as a Finalist in the RISING STAR OF THE YEAR category for the INTERNATIONAL GAMING AWARDS (https://ibn.fm/PPw02). The IGA will take place onSeptember 8 at The Savoy Hotel in London.  Mobius Interactive’s partner and platform provider, UltraPlay, is an Esports pioneer, having won multiple awards over the past few years. Mobius Interactive differentiates itself from its competitors by its use of top affiliates, a focus on Esports, customer relationship management, loyalty programs, and superior gamification. Mobius Interactive is open for investment opportunities. For further information please contact: Gary Eldridge – President 1 (604) 783-1685 gary@mobiusinteractive.ltd Seamus Byrne – VP Corporate Development 1 (902) 441-5757 seamus.byrne@mobiusinteractive.ltd For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• AI models of genomic data can predict cancer outcomes, which can then help personalize ovarian cancer treatments
• Results come from Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research Library
• Model learns patterns in genetic mutations of patients’ tumors, uses that knowledge to predict patient survival

In an historic announcement in the space where artificial intelligence and precision medicine intersect, Predictive Oncology (NASDAQ: POAI) has released initial results for its AI-driven models of ovarian cancer (https://ibn.fm/H3As3). According to Predictive Oncology, the initial results demonstrate that AI models of genomic data can predict cancer outcomes which has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies. “We are excited to be able to show the impact of using our AI and machine learning approach that leverages complex genomic data to deliver improved, more personalized therapy for ovarian cancer that, worldwide, affects over 300,000 women,” said Predictive Oncology CEO J. Melville Engle. “We are continuing to refine these AI models with the goal of providing highly accurate predictive models of ovarian cancer to help oncologists and drive the development of the next generation precision ovarian cancer therapies.” The results come from POAI subsidiary Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research Library (“NGRL”). Helomics has created a new AI-driven model that predicts post-treatment survival time for ovarian cancer patients. According to the company, these AI models have the potential to not only improve treatment paths for ovarian cancer but also to drive the development of new therapies. POAI noted that official study results will be available as a preprint on Biorxiv in the coming weeks. To build the model, Helomics used a machine learning approach to extract key genomic features from nearly 500 ovarian cancer participants in the 100,000 Genomes Project. The AI model learned patterns in the genetic mutations of patients’ tumors and then used that knowledge to predict survival time. The model predicted rates with almost 70% accuracy. With that success as a backdrop, Helomics is now focused on refining its AI models to achieve an even greater accuracy for predictions. The news is notable in the world of oncology because no biomarkers for prognosis and treatment responses in ovarian cancer currently exist, making it difficult for health-care providers to tailor treatments for individual patients. Instead, doctors are forced to choose from a set “menu” of drugs and therapies, observed POAI, a menu that has seen little progress in more than 20 years, even with the significant amount of research devoted to cancer. Using the predictions of patients’ responses to certain therapies, Helomics’ AI model could assist health-care providers in narrowing down the ovarian cancer treatment options, thereby improving patients’ prognosis and offering clinicians a more efficient and cost-effective precision medicine approach to treatment. These models also give doctors and scientists better insights into which genes are involved in response to treatment, which could lead to the development of new precision medicines. “We’re delighted that our multiyear partnership with Helomics has resulted in this important research into ovarian cancer — a disease with significant unmet need,” said Parker Moss, chief commercial and partnership officer at Genomics England. “We are incredibly grateful to the around 900 participants in the 100,000 Genomes Project who suffer from ovarian cancer and have made their data available for this ground-breaking research. Genomics England is pleased to have contributed to Helomics’ work through our ovarian cancer dataset, as this has allowed them to validate their discoveries and create predictive models that will advance drug discovery and support ovarian cancer patients and their doctors.” POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the Company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the Company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• FuelPositive Corp. is a Canadian clean energy innovator intent on developing manufacturing, licensing and acquisition opportunities, particularly through the development of a carbon-free ammonia production IP
• The company’s solution, its Phase 2 Hydrogen-Ammonia Synthesizer, is a commercial prototype designed to be transportable, scalable, and efficient in producing carbon-free ammonia for a range of applications
• Green innovations in ammonia production can immediately benefit the agricultural industry, but also have the potential to create ammonia/hydrogen fuel alternatives to pollutant-heavy petroleum used in internal combustion engines and new ammonia-based storage options for electrical grids
• FuelPositive began trading on the OTCQB Venture Marketplace last month, adding to its investor profile on the TSX Venture Exchange in Canada

When climate visionaries talk about the possibilities of a carbon-free energy future, many people imagine landscapes covered with solar panels and wind turbines favored as a means of producing “clean” energy. Recognizing that internal combustion engine vehicle emissions remain the largest contributor to greenhouse gas emissions in the United States and many other parts of the world, it’s no surprise that debates about electric vehicle (“EV”) adoption also are ticking upward (https://ibn.fm/X9Ebn). Canadian-based FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a licensing and acquisition opportunity developer, is intent on supporting clean energy technologies, particularly ammonia produced in a carbon-free manner for use in a variety of applications. The company is encouraging governments and industries to adopt this significant approach to improving the environment, which includes the possibility of reducing fossil fuel combustion engine emissions in large engines, along with many other applications. But first, FuelPositive is targeting existing ammonia production methods that sustain a multi-billion-dollar global industry tied to world food commerce that creates a large proportion of the greenhouse emissions polluting the planet’s ecosystem. FuelPositive is developing a patent-pending, first-of-its-kind carbon-free method of producing ammonia as its flagship technology to reduce the impact of pollution in ammonia’s commercialization. When used properly, the only discernable emissions from the technology will be water vapor, or, in the case of agriculture, some inert hydrogen emissions. “Until now, the production of ammonia has been one of the most carbon-intense manufacturing processes on the planet, and given the amount of ammonia that is used on an annual basis in a variety of applications, ammonia is a serious negative contributor to greenhouse gases and global warming,” CEO Ian Clifford stated earlier this year (https://ibn.fm/q23Nj). “This development, in sustainable ammonia, and the creation of carbon-free NH3 that is far more efficient than current manufacturing systems, could pave the way for the broad acceptance of ammonia as a fossil fuel replacement.” The technology behind the solution is FuelPositive’s Phase 2 Hydrogen-Ammonia Synthesizer commercial prototype systems. The company anticipates rolling out the first demonstration models early next year through an agreement with National Compressed Air Canada Ltd. (https://ibn.fm/sDNpn). A commercial-scale, carbon-free method of producing ammonia could immediately benefit the agricultural industry with a non-polluting source of fertilizer, but it also has the potential to expand its usefulness to other sectors. A renewable fuel alternative for combustion engines through its hydrogen conversion process, electrical grid storage solutions drawing on ammonia’s high energy density, and electricity provision to northern / remote communities thanks to the technology’s portability are all ways FuelPositive may fulfill its potential. Ammonia’s chemical composition of three hydrogen atoms and one nitrogen results in an energy density by volume that is nearly double that of liquid hydrogen. Liquid hydrogen has been the focus of many renewable energy efforts, but ammonia not only contains a significant amount of hydrogen, it is easier to ship and distribute than liquid hydrogen (https://ibn.fm/ysmXb). “Our (Hydrogen-Ammonia Synthesizer) systems are small, they’re about the size of a shipping container that you would see on an ocean-going ship, and we can move them all over the place. So they can be used exactly where the ammonia is needed, so we don’t have to transport ammonia all over the place,” Clifford recently told a group of young investment advisers (https://ibn.fm/6hHpF). “We think our company will grow a lot in value over the next six to 12 months as our systems are delivered to end users — the people who need the ammonia.” Considering the rapidly growing effects of worldwide global warming, and the serious role that traditional ammonia production plays in that process, FuelPositive’s technology, and the potential for significant reduction in greenhouse gases that it represents, is of global importance. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• The company reported revenues of $9.7M, in-line with Q1 2021’s sales while gross profit improved to $2.1M, up 16% quarter over quarter
• Excellon’s production cost per tonne decreased to $273, down 8% quarter over quarter
• The company also increased its exploration expenditures to $1.8M in Q2 2021, with ongoing mining activity at Mexico’s Platosa mine, as well as in their German and Idaho-based sites

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with precious metal projects in Mexico, Idaho and Germany, has recently published their second quarter results for the 2021 fiscal year. The Company reported Q2 2021 revenues of $9.7 million, up from the $0.7 million registered in Q2 2020, while gross profit improved to $2.1 million, a significant improvement from last year when there was a loss of -$2.6 million. Excellon Resources also reported that the company had cash and marketable securities totalling $7.1 million at hand as of June 30, 2021. Excellon Resources’ strong second quarter results were directly correlated to the robust production numbers generated from the Platosa Mine in Durango, Mexico. Excellon saw silver production of 296,013 ounces, lead production of 1.9 million pounds and zinc production of 2.5 million pounds – in aggregate totalling silver equivalent production of 487,009 ounces. Although comparative results relative to the equivalent period in 2020 were impacted by the suspension of activities in Mexico from April 2, 2020 to June 1, 2020 on account of the COVID-19 outbreak, the second quarter of 2021 marked the fourth consecutive quarter of over 21,000 tonnes mined and milled. “Platosa delivered a fourth consecutive quarter of production at historically high productivity rates,” stated Brendan Cahill, President & CEO of Excellon Resources (https://ibn.fm/eE7Hs). “We continue to see room for improvement, with our ongoing work to improve recoveries at Miguel Auza and, additionally, a sizeable inventory of ore and concentrate at quarter-end due to mill maintenance and weather conditions in late June.” In addition to the high productivity rates witnessed within the company’s operations, Excellon Resources were simultaneously able to reduce their marginal cost of extraction. Production cost per tonne decreased to $273 per tonne, a decline of 8 percent relative to the first quarter of 2021, with the all-in sustaining cost per silver ounce payable decreasing to $26.69 per ounce (https://ibn.fm/KPgIy). Exploration expenditures rose by 597 percent year over year and by 80 percent quarter over quarter to $1.8 million as drilling operations continued to ramp up across various sites. Excellon Resources has recently commenced the process of drilling and adding a second rig at the Silver City site in Germany’s Saxony following the approval of the 2021 drilling operation plan, and it has looked to expand surface and underground drilling operations on multiple targets within the Platosa Mine property. Additionally, the company has commenced drilling at the Oakley Project in conjunction with Centerra Gold Inc. “The operation delivered good improvements in cost-per-tonne and cash costs, while AISC was higher in the quarter due to sustaining capital expenditures, a part of which had been deferred from earlier periods,” stated Cahill. “Most importantly, we continued to ramp-up exploration on our projects, with Platosa ongoing and Silver City and Oakley getting started. We look forward to drilling results from our resource growth and discovery-focused projects through the remainder of the year.” For more information, visit the company’s website at www.ExcellonResources.com. NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

• Canada-based life sciences company Mind Cure Health is pursuing innovative technology and research solutions to improve mental health through technology
• The company is focused on developing digital therapeutics technology and researching psychedelic compounds
• The company’s proprietary software-as-a-service (SaaS) platform iSTRYM is designed to increase transparency and awareness between patients and therapists
• On the research side, Mind Cure Health is also manufacturing synthetic ibogaine and currently determining the commercialization potential of two different pathways for production
• Mind Cure Health recently announced an agreement with experienced clinical psychologist Dr. Ken Weingardt to guide iSTRYM toward near-term commercial deployment

A growing number of researchers in the medical science field are investigating the potential of psychedelic drugs to open a new field of medicinal solutions. Legislators as well as wider segments of society are also beginning to take notice. Canada-based Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) is devoted to building access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. The company has filed a provisional patent application for its pharmaceutical-grade synthetic ibogaine to be used in clinical research and anticipates developing that in conjunction with its software-as-a-service (SaaS) platform iSTRYM, which is designed to help patients and physicians manage psychiatric medications using smart “digital therapeutics” technology. To further the company’s goals, Mind Cure Health announced Aug. 10 an agreement with Dr. Ken Weingardt in which Weingardt will provide consulting services as a senior clinical technology advisor. Weingardt is a clinical psychologist with 20 years of experience working at the intersection of technology and behavioral health, according to the company (https://ibn.fm/bqm92). Weingardt will guide iSTRYM toward near-term commercial deployment, building clinical excellence in both commercial deployment and design. “This company is among the first to develop a digital therapeutic specifically designed to support the process of psychedelic-assisted therapy. I am delighted to advise the team as they leverage innovative technologies to potentially reduce symptoms, improve quality of life, and support transformation and healing,” Weingardt stated in the company’s news release. The company anticipates making iSTRYM available to select clinics during the current Q3 period and launching the software broadly and commercially during the first few months of next year. The product launch will initially be aimed at psychedelic centers but will later expand to integrated clinics, both traditional and psychedelic, and eventually the broader mental health market, according to the company. Mind Cure Health plans to file for FDA approval under the software as a medical device (“SaMD”) pathway, which it expects to speed reimbursement. iSTRYM will be a fee-based service to help clinics ideally create better care and outcomes for their patients. Mind Cure Health’s synthetic ibogaine research aims to develop a potential treatment for traumatic brain injury, neuropathic pain and migraines. The company indicates ibogaine may also help repair and rewire the brain’s neural pathways in treating drug addiction. The company recently announced it had launched the second stage of manufacturing synthetic ibogaine after completing proof-of-concept protocols that tested the chemistry and development route for successfully manufacturing ibogaine. The second stage will focus on the scale-up process by establishing financial models in tandem with assessments of the quality of the synthetic ibogaine to determine the economic viability of commercial scaling (https://ibn.fm/Au7Kn). For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• It has become known that COVID-19 patients can present with neurological symptoms, but new comprehensive cross-country study indicates that it could be more prevalent than previously thought
• This could represent enormous challenge to healthcare as it needs to prepare for immediate and longer-term rehabilitation care of these patients
• Brain Scientific is committed to remaining at forefront of brain diagnostics, potentially offering solution to higher need for neurological care of COVID-19 patients

Brain Scientific (OTCQB: BRSF), a commercial-stage health care company on a mission to modernize brain diagnostics, could be the one offering solution to the rising challenge global healthcare systems face in the post-Covid world. As scientists are starting to collect more and more data, they can decipher both immediate and longer-term consequences of SARS-CoV-2 infection. Research has been mounting demonstrating that some infected patients suffer from neurological symptoms, including memory loss, stroke, and other effects on the brain (https://ibn.fm/CM7uW). However, the new comprehensive cross-country study recently published in the Journal of Neurology, Neurosurgery, and Psychiatry reveals that neurological symptoms may actually be the norm rather than an exception (https://ibn.fm/s3uJw). A new systematic review and meta-analysis conducted by University College London examined 215 COVID-19 studies across 30 different countries involving 105,638 symptomatic COVID-19 patients from January to July 2020. The research team was expecting to find neurologic and psychiatric findings to be more common in severe COVID-19. Instead, they found that some of these symptoms appeared to be more common in mild cases, indicating that COVID-19 affecting the brain could be the norm, rather than the exception as previously thought. The study also demonstrates no clear link of these symptoms to systemic or respiratory symptoms. According to the authors, the most prevalent neurological symptoms actually occurred more frequently in patients with less severe COVID-19. This finding could indicate that neurological symptoms are not necessarily correlated with systemic or respiratory symptoms. As we learn more about COVID-19, it is becoming increasingly clear that neurological care in the post-Covid world will be crucial. In the words of the authors, with millions of people infected globally, even the rarer symptoms could affect considerably more people than in normal times. Due to the sheer scale of the pandemic, this could potentially represent a massive challenge to healthcare systems that need to prepare both for the immediate care of these patients and their longer-term rehabilitation needs. In an environment like this, Brain Scientific’s next-generation technological solutions for the neurology market could become critical as they offer EEG testing to be deployed rapidly and accurately in children and adults alike. The company’s two FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM), allow quick and reliable EEG testing in minutes and by any healthcare worker, not only specialized neurological technicians, bringing brain diagnostics to settings where it was previously impossible or difficult to conduct neurological testing. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Cooperation and partnership discussions: AnPac Bio has reported major corporations in the medical industry include Roche Pharmaceuticals China and Advanced Life Therapeutics Co., Ltd
• AnPac Bio holds 40% minority equity in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devices
• AnPac Bio’s board now includes Mr. Chao Feng who has global fortune 500 Companies’ managerial experience as independent director effective July 19, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), an innovative thought leader and biotechnology company focused on early screening and cancer detection by developing, distributing, and deploying accessible early disease detection devices, announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holding AG, to explore novel healthcare and medical solutions. The collaboration will leverage both parties’ advantages and resources to work on early cancer screening, diagnosis, and treatment (https://ibn.fm/4PpPO). AnPac Bio is an early thought leader and innovator in the field of cancer screening, where it has already made notable contributions including as an early thought leader and technology leader of multi-(pan) cancer screening and multi-level and multi-parameter innovation and screening products. By 2014, AnPac Bio announced that the cancer detection technology it developed was capable of screening 16 types of cancer, and was one of the earliest companies to begin marketing a pan-cancer screening and detection test in 2015, when it began commercial operations. Per the agreement signed by AnPac Bio and Roche, both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (“CDA”) cancer detection technology and Roche’s FoundationOne CDx to create a solution that customers with a high cancer risk level as assessed by CDA and later diagnosed with cancer can receive a personalized CDx precision medical test for therapy selection. The parties aim to help benefit the general population while lowering costs and saving patient lives. Th cancer screening and diagnostic market is expanding, with the number of cancer cases reported worldwide also growing. According to the World Health Organization (“WHO”), there were 135 million cancer patients globally in 2020, with 32 million geographically located in China. The new figures mark a 20 million increase in the number of worldwide cases, 4.7 million of which in China. The cooperation agreement with Roche comes after AnPac Bio’s agreement with Advanced Life Therapeutics Co., Ltd. The company holds minority equity of 40% in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devices (https://ibn.fm/RIHTd). The partnership with Advanced Life Therapeutics is a multi-year contract to design, fabricate, test, and optimize key components of a cancer treatment medical device. AnPac Bio expects to begin generating revenue from this contract R&D project starting Q3 of this year. AnPac Bio is in the later stages of cooperation and partnership discussions with multiple major corporations in the medical industry aimed at increasing commercial CDA-based cancer test revenue and broadening a new product pipeline for itself and its partners. The agreements with Advanced Life Therapeutics and Roche announced recently. Effective July 19, 2021, Mr. Chao Feng was named as her successor to take the role of independent director immediately (https://ibn.fm/IDUPZ), with Ms. Lin Yu resigned as the director of AnPac Bio.  Having previously worked for two global Fortune 500 companies in China, Mr. Chao Feng served as general manager for Shanghai Zhiruihaochen Information Technology Co., Ltd. since 2019. Additionally, he has been the chairman of the strategy committee of Guangzhou Chengding Robots Co., Ltd. since 2016. In his role as the new independent director of AnPac Bio, Mr. Feng said, “AnPac Bio has been recognized in the field of early cancer screening and detection, and I’m excited to be a part of the team. I look forward to contributing to AnPac Bio’s future success as a member of its Board and helping the Company in its further development.” Dr. Chris Yu, CEO and Chairman of the Board for AnPac Bio, welcomed Mr. Feng to the team, praising his experience. “His strong academic background and business management experience, particularly in strategic planning, capital market transactions, and sales, will benefit our Company in our pursuit of long-term growth,” Dr. Yu said. Through its CDA technology, AnPac Bio aims to tackle multiple aspects and challenges of the cancer screening and diagnostics industry. Using the natural biophysical properties of blood and cellular proteins to discover cancerous environments within the body before the tumors form and being powered by a database of over 200,000 samples and cases, CDA has been able to diagnose and identify pre- and early-stage cancers in patients that were previously diagnosed as cancer-free through traditional methods. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

The Q3 Investor Summit is being held on August 17-18, 2021, offering numerous networking for attending companies and investors. The conference will feature 70+ companies and 800 investors, as well as media assets for additional marketing opportunities. The 2-day event will feature small and micro-cap companies attending the conference who can avail its high-quality content offered by distinguished industry speakers. Investors will be attending to learn about the latest investor trends and do business with the presenting companies. The market cap participation includes:

• $100-$300 (22%)
• $300M+ (24%)
• Under $500M (33%)
• $50 – $100M (21%)

The summit’s investors include:

• Family Office (12%)
• HNW (9%)
• Institutional (61%)
• RIAs (18%)

The Q3 Investor Summit has businesses, entrepreneurs and institutions from the healthcare, consumer, financial, technology, cannabis, blockchain and industrial sectors looking for growth, investment and networking opportunities. Startups and emerging growth companies can leverage the investor connections at this forum to expand their business. Investor Summit’s online platform gives new companies and well-established leaders an excellent growth avenue where they can be discovered by the investment community. This exceptional conference is attended by industry stalwarts and has garnered a reputation for introducing new companies to a wide spectrum of the global investment community. The virtual event has a well-lined up presentation schedule. There are 3 topical panels where you can listen in to avail the knowledge and insights imparted by the community influencers. There is also a 30-minute webcast with Q&A, and all the content will be available on the conference website for 90 days. The Q3 Investor Summit’s one-to-one meetings, high-level discussions and engaging keynotes from eminent industry leaders and thinkers should not be missed. For more details, please visit https://investorsummitgroup.com